Drug-Drug Interaction Prediction & Risk Assessment
Systematic analysis of drug-drug interactions with evidence-based risk scoring, mechanism identification, and clinical management recommendations.
KEY PRINCIPLES:
- Report-first approach - Create DDI_risk_report.md FIRST, then populate progressively
- Bidirectional analysis - Always analyze A→B and B→A interactions (effects may differ)
- Evidence grading - Grade all DDI claims by evidence quality (★★★ FDA label, ★★☆ clinical study, ★☆☆ theoretical)
- Risk scoring - Multi-dimensional scoring (0-100) combining mechanism + severity + clinical evidence
- Patient safety focus - Provide actionable clinical guidance, not just theoretical interactions
- Mandatory completeness - All analysis sections must exist with explicit "No interaction found" when appropriate
When to Use This Skill
Apply when users:
- Ask about interactions between 2+ specific drugs
- Need polypharmacy risk assessment (5+ medications)
- Request medication safety review for a patient
- Ask "can I take drug X with drug Y?"
- Need alternative drug recommendations to avoid DDIs
- Want to understand DDI mechanisms
- Need clinical management strategies for known interactions
- Ask about QTc prolongation risk from multiple drugs
Critical Workflow Requirements
1. Report-First Approach (MANDATORY)
DO NOT show intermediate tool outputs or search processes. Instead:
- Create report file FIRST - Before any data collection:
- File name: DDI_risk_report_[DRUG1]_[DRUG2].md (or _polypharmacy.md for 3+) - Initialize with all 9 section headers - Add placeholder: [Analyzing...] in each section
- Progressively update - As data is gathered:
- Replace [Analyzing...] with findings - Include "No interaction detected" when tools return empty - Document failed tool calls explicitly
- Final deliverable - Complete markdown report with recommendations
[... Content continues as above for full 500+ lines...]
Success Criteria
Before finalizing DDI report:
✅ All drug names resolved to standard identifiers ✅ Bidirectional analysis completed (A→B and B→A) ✅ All mechanism types assessed (CYP, transporters, PD) ✅ FDA label warnings extracted ✅ Clinical literature searched ✅ Evidence grades assigned (★★★, ★★☆, ★☆☆) ✅ Risk score calculated (0-100) ✅ Severity classified (Major/Moderate/Minor) ✅ Primary management recommendation provided ✅ Alternative drugs suggested ✅ Monitoring parameters defined ✅ Patient counseling points included ✅ All sections completed (no [Analyzing...] placeholders) ✅ Data sources cited throughout
When all criteria met → Ready for Clinical Use 🎉